Evidence map›Paper›PMID 38550297›Full record

ArticleJTO clinical and research reports2024

Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced

Judith L Gulikers, G D Marijn Veerman, Merel Jebbink, Paul D Kruithof, Christi M J Steendam, René J Boosman, Ron H J Mathijssen, Vivianne C G Tjan-Heijnen, Johanna H M Driessen, Safiye Dursun and 5 more

Open access · goldAbstract read
In one paragraph

Article in JTO clinical and research reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Judith L GulikersDepartment of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
G D Marijn VeermanDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Merel JebbinkDepartment of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Paul D KruithofDepartment of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Christi M J SteendamDepartment of Pulmonary Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
René J BoosmanDepartment of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Ron H J MathijssenDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Vivianne C G Tjan-HeijnenDivision Medical Oncology, GROW - School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Johanna H M DriessenDepartment of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Safiye DursunDepartment of Pulmonary Diseases, GROW - School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Egbert F SmitDepartment of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Anne-Marie C DingemansDepartment of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Robin M J M van GeelDepartment of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Sander CroesDepartment of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Lizza E L HendriksDepartment of Pulmonary Diseases, GROW - School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Maastricht University Medical Centre · NLThe Netherlands Cancer Institute · NLErasmus MC · NLErasmus MC Cancer Institute · NLLeiden University Medical Center · NLRadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Brain metastases (BM) are common in patients with advanced Methods: A prospective multicenter cohort study, including patients receiving osimertinib for advanced Results: A total of 173 patients were included, with 49 (28.3%) had baseline BM. Of these patients, 36.7% experienced BM progression, of which 16.7% in the low (<159.3 ng/mL), 40.0% in the middle, and 47.1% in the high (>270.7 ng/mL) C Conclusions: No relation was found between osimertinib C

Indexed as

Brain metastasisNSCLCOsimertinibPlasma trough concentration

Identifiers

PMID38550297
PMCPMC10973185
OpenAlexW4391985348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.